Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.51 |
| ▸ | CA2 | P00918 | 10/20 | 0.51 |
| ▸ | CA9 | Q16790 | 10/20 | 0.51 |
| ▸ | LPL | P06858 | 6/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24246039 | 0.91 | CA1 (0.46) | CA1CA2CA9LPLLIPG | |
| SCHEMBL443866 | 0.89 | MEN1 (0.52) | CA1CA2CA9LPLLIPG | |
| SCHEMBL22683677 | 0.86 | HDAC1 (0.54) | CA1CA2CA9LPLLIPG | |
| SCHEMBL443260 | 0.86 | CA1 (0.49) | CA1CA2CA9LPLLIPG | |
| SCHEMBL2380393 | 0.86 | CA1 (0.49) | CA1CA2CA9LPLLIPG | |
| SCHEMBL444777 | 0.85 | CA1 (0.48) | CA1CA2CA9LPLLIPG | |
| SCHEMBL3732362 | 0.85 | CA1 (0.48) | CA1CA2CA9LPLLIPG | |
| SCHEMBL440971 | 0.85 | CA1 (0.51) | CA1CA2CA9LPLLIPG | |
| SCHEMBL440627 | 0.85 | CNR1 (0.57) | CA1CA2CA9LPLLIPG | |
| SCHEMBL3322268 | 0.83 | LPL (0.45) | CA1CA2CA9LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695251-A1 | IMIDAZO[1,2-A]PYRAZINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024213656-A1 | IMIDAZO[1,2-A]PYRAZINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| EP-3475285-B1 | MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2022-02-09 | — | — | EP | disclosed |
| EP-3475285-B1 | MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-11242346-B2 | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-11242346-B2 | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2022-02-08 | — | — | US | disclosed |
| CN-109641909-B | Mechanism targets for rapamycin signaling pathway inhibitors and therapeutic applications thereof | 苏州开拓药业股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-109438447-B | Preparation method and application of 5, 7-dihydro-6H-pyrrolo [2,3-d ] pyrimidine-6-ketone derivative | 北京工业大学 | 2020-10-16 | — | — | CN | disclosed |
| US-20200181147-A1 | MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2020-06-11 | — | — | US | disclosed |
| US-20200181147-A1 | MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2020-06-11 | — | — | US | disclosed |
| WO-2010151601-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151601-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010124826-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010103094-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2010014939-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010014939-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | CA1 4862/4885CA2 3359/4885CA9 4879/4885 |
| US-11242346-B2 | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | MTOR, RPTOR, RICTOR | CA1 4779/4885CA2 4398/4885CA9 4209/4885 |
| US-20200181147-A1 | MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | MTOR, RPTOR, RICTOR | CA1 4779/4885CA2 4398/4885CA9 4209/4885 |
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | CA1 4813/4885CA2 4576/4885CA9 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.